[68Ga]Ga-DOTA-FAPI-04 PET/CT在胸腺上皮肿瘤评估中优于[18F]FDG PET/CT
该前瞻性研究纳入57例疑似胸腺上皮肿瘤(TETs)患者,所有患者均在1周内完成[18F]FDG与[68Ga]Ga-DOTA-FAPI-04 PET/CT。结果显示[68Ga]Ga-DOTA-FAPI-04 PET/CT在区分胸腺瘤与胸腺癌(AUC 0.99 vs. 0.90,P=0.02)、鉴别低危/高危胸腺瘤及胸腺癌、评估Masaoka-Koga分期及转移状态方面均优于[18F]FDG PET/CT。
要点
- [68Ga]Ga-DOTA-FAPI-04 PET/CT区分胸腺瘤与胸腺癌的AUC为0.99,优于[18F]FDG PET/CT的0.90(P=0.02)。
- SUVmax-FAPI与TMR-FAPI在鉴别低危胸腺瘤、高危胸腺瘤及胸腺癌方面均表现出优异能力(均P<0.001)。
- [68Ga]Ga-DOTA-FAPI-04 PET/CT检测淋巴结转移特异性93%(64/69)高于[18F]FDG的67%(46/69),评估远处转移灵敏度97%(38/39)高于[18F]FDG的49%(19/39)。
核心结论
- [68Ga]Ga-DOTA-FAPI-04 PET/CT在评估TETs的世界卫生组织(WHO)分类、Masaoka-Koga分期及转移状态方面优于[18F]FDG PET/CT。
研究设计与样本
- 前瞻性研究,纳入2021年4月至2022年11月经组织病理学或随访影像确认的疑似TETs患者57例,所有患者均在1周内完成[18F]FDG与[68Ga]Ga-DOTA-FAPI-04 PET/CT。
主要发现
- [68Ga]Ga-DOTA-FAPI-04 PET/CT区分胸腺瘤与胸腺癌的AUC为0.99,优于[18F]FDG PET/CT的0.90(P=0.02)。
- 逻辑回归显示SUVmax-FAPI是胸腺癌的显著预测因素(P=0.04)。
- SUVmax-FAPI与TMR-FAPI在鉴别低危胸腺瘤(A、AB、B1型)、高危胸腺瘤(B2、B3型)及胸腺癌方面均表现出优异能力(均P<0.001)。
- 在胸腺瘤中,仅SUVmax-FAPI(P<0.001)、TMR-FAPI(P<0.001)及边缘不光滑(P=0.02)在晚期组(Masaoka-Koga III/IV期)显著高于早期组(I/II期)。
- 与[18F]FDG PET/CT相比,[68Ga]Ga-DOTA-FAPI-04 PET/CT检测淋巴结转移特异性更高(93%[64/69] vs. 67%[46/69],P<0.001),评估远处转移灵敏度更高(97%[38/39] vs. 49%[19/39],P<0.001)。
关键数值与推荐
- 区分胸腺瘤与胸腺癌AUC:[68Ga]Ga-DOTA-FAPI-04 PET/CT 0.99 vs. [18F]FDG PET/CT 0.90(P=0.02)。
- 淋巴结转移检测特异性:[68Ga]Ga-DOTA-FAPI-04 PET/CT 93%(64/69)vs. [18F]FDG PET/CT 67%(46/69),P<0.001。
- 远处转移评估灵敏度:[68Ga]Ga-DOTA-FAPI-04 PET/CT 97%(38/39)vs. [18F]FDG PET/CT 49%(19/39),P<0.001。
- SUVmax-FAPI与TMR-FAPI鉴别低危胸腺瘤、高危胸腺瘤及胸腺癌的P值均<0.001。
临床怎么用
- 原文结论认为[68Ga]Ga-DOTA-FAPI-04 PET/CT在评估TETs的WHO分类、Masaoka-Koga分期及转移状态方面优于[18F]FDG PET/CT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study is to compare the ability of [68Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT to stratify the malignancy and invasiveness of thymic epithelial tumours (TETs). METHODS: From April 2021 to November 2022, participants with suspected TETs confirmed by histopathology or follow-up imaging were prospectively analysed. All participants underwent [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT within 1 week. Clinical characteristics, CT features, and metabolic parameters (maximum standardized uptake value [SUVmax] and tumour-to-mediastinum ratio [TMR]) of subjects with different pathological types and stages were compared. The diagnostic capacities of [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT were compared using receiver operating characteristic (ROC) curves and McNemar's test. RESULTS: Fifty-seven participants were included. [68Ga]Ga-DOTA-FAPI-04 PET/CT was superior to [18F]FDG PET/CT in differentiating thymomas from thymic carcinomas (TCs) (AUC: 0.99 vs. 0.90, P = 0.02). Logistic regression revealed that SUVmax-FAPI (P = 0.04) was a significant predictive factor for TCs. SUVmax-FAPI and TMR-FAPI showed an excellent ability to differentiate low-risk thymomas (types A, AB, and B1), high-risk thymomas (types B2 and B3), and TCs (both P < 0.001). In thymomas, only SUVmax-FAPI (P < 0.001), TMR-FAPI (P < 0.001), and nonsmooth edges (P = 0.02) were significantly higher in the advanced-stage (Masaoka-Koga [MK] stage III/IV) group than in the early-stage group (MK stage I/II). Compared with [18F]FDG PET/CT, [68Ga]Ga-DOTA-FAPI-04 PET/CT showed significantly higher specificity (67% [46 of 69] vs. 93% [64 of 69], P < 0.001) in the detection of lymph node metastases and higher sensitivity (49% [19 of 39] vs. 97% [38 of 39], P < 0.001) in evaluating distant metastases. Both SUVmax-FAPI and TMR-FAPI were correlated with FAP expression (both r = 0.843, P < 0.001). CONCLUSION: [68Ga]Ga-DOTA-FAPI-04 PET/CT was superior to [18F]FDG PET/CT in evaluating the World Health Organization (WHO) classification, MK staging, and metastatic status of TETs. TRIAL REGISTRATION: ChiCTR2000038080, registration date 2020-09-09, https://www.chictr.org.cn/com/25/showproj.aspx?proj=61192.
引用
- Shen X, Zhou X, Yao Y, et al. Superiority of [68Ga]Ga-DOTA-FAPI-04 PET/CT to [18F]FDG PET/CT in the evaluation of thymic epithelial tumours. Eur J Nucl Med Mol Imaging. 2023. PMID: 37316675. doi:10.1007/s00259-023-06294-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。